System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Riitta Lassila

Hematology — Helsinki University Hospital, Finland

LeadR Profile

Riitta Lassila Helsinki University Hospital Finland
893 ScienceLeadR Reputation 893

Unlock

Register Login
Network Map

Hematology

Subspecialties: Cardiology - Public Health - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Organizations

Source: Pubmed

Helsinki University Hospital

Publications Synthesis

Source: Pubmed

Number : 311

Citations

Citations: 13 541 1st author: 30 Last author: 102 Unique author: 16

Main journals

Haemophilia 36
Thromb Res 29
Duodecim 20
Thromb Haemost 17
Res Pract Thromb Haemost 11

Best Journals

N Engl J Med 3

Breakdown by type

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The landmark contribution by Erik von Willebrand.
hematology, hemorrhage, work, hemophilia a		Haematologica20260
Seventh Åland Island Meeting on von Willebrand Disease.
diagnostic techniques and procedures, von willebrand diseases, hemophilia a, therapeutics		Haemophilia20260
Interactions of dual antiplatelet and anticoagulant with C1q and FH regulate complement activation by injured cells.
cells, anticoagulants, serum, thrombin, heparin, thp-1 cells, complement system proteins, complement activation, plasma		Blood Vessel Thromb Hemost20260
Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.
hemorrhage, phenotype, classification, hemophilia a, diagnosis		Hemasphere20250
Invitation and welcome to the 2025 ISTH Congress.
thrombosis		J Thromb Haemost20250

Clinical Studies 5

Source: ClinicalTrials

Synthesis

Sub-Investigator: 1

By phase:

N/A 1
Phase 2 1
Phase 2/Phase 3 1
Phase 3 1
Phase 4 1

By status:

Completed 4
Active not recruiting 1

By type:

Interventional 4
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 1

Main Topics

Congenital, Hereditary, and Neonatal Diseases and Abnormalities 2
Hemic and Lymphatic Diseases 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Convalescent Plasma in the Treatment of Covid 19
NCT04730401 — safety, covid-19, therapeutics, plasma		Phase 2Active not recruiting2021

LeadR Networks

Main global connection map

Source: Pubmed Source: ClinicalTrials